Articles On Bionomics (ASX:BNO)

On Stockhead today: Aussie small caps trying to tackle the opioid crisis, which car manufacturers will survive the EV revolution, Barry FitzGerald looks at upcoming juniors, and how South Australian small caps are putting themselves back on...

Each Monday, Stockhead recaps which stocks are heavily demanded by investors – or running hot. Stockhead uses the Relative Strength Index (RSI), a technical gauge which measures how trading momentum is affecting the price action. A reading...

On Stockhead today, why the ASX thinks the tech IPO story has further to run, McKinsey & Co say private equity needs to get more entrepreneurial and while low interest rates might make wealth creation harder, it’s not impossible, expert...

The Bionomics Ltd (ASX: BNO) share price shot up 41% today after the biotechnology researcher announced its PTSD drug labelled BNC210 had delivered positive results from a clinical trial. In five healthy male volunteers it was found that t...

Shares in Bionomics (ASX:BNO) have flown to their highest point since May as it looks redo the failed post traumatic stress disorder trial that wiped out 66 per cent of the company’s value last October. Bionomics conducted a pharmacokinetic...

Biopharma company Bionomics (ASX: BNO) has updated the market with positive news regarding its leading drug candidate BNC210, a potentially new way of treating patients with post-traumatic stress disorder (PTSD). Earlier this morning, the c...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Bionomics (ASX:BNO) has announced positive results from a pharmacokinetic study in healthy volunteers using the newly developed solid dose formulation of its lead drug candidate, BNC210.

Coming after trial flops from Factor Therapeutics (ASX:FTT), Innate Immunotherapeutics (now Amplia Therapeutics, ASX:ATX) and Bionomics (ASX:BNO), investors were awaiting the phase IIb results from the eye diseases house with more than a de...

On 15 August 2019, the S&P/ASX 200 Health Care Index is down 2.48% to 34,883, while the benchmark index S&P/ASX 200 was down by 2.65% and trading at 6,425.5 (as at AEST: 2:08 PM). In this article, we will discuss four stocks that ar...

Zelda Therapeutics Ltd (ASX: ZLD) Cannabis Group Zelda Therapeutics released its quarterly results for the three months ended 30 June 2019. The company reported a continued progress in its core clinical and preclinical programs and is in th...

Companies and institutions that provide medical assistance and services, manufactures of medical equipment, engage in clinical trials and development of drugs, are part of the healthcare sector. The Australian government makes significant c...

Book Value of Equity Per Share (BVEPS) is the sum each common equity shareholder receives at the time company goes into liquidation. In other words, it is equivalent to firm’s net asset value, i.e. total assets minus total liabilities, on a...

In this week's Weekly Insights (published in two parts):-Do I Have A Few Surprises For (Most Of) You! -M&A Is Back; Who's The Next Target? -Conviction Calls -Three Charts To Mark Mid-2019 -Caveat Emptor: Retail Landlords-Rudi On Tou...

The small-cap or ‘casino’ end of the share market is a veritable minefield suitable for highly-experienced investors only. However, this does not stop beginner investors or speculators regularly trading shares in the hope of a quick profit...

Dimerix Limited (ASX: DXB) Clinical-stage biopharmaceutical company, Dimerix Limited (ASX: DXB) is engaged in developing new therapies for the unmet requirements of the medicine market all over the world. On 26 June 2019, Dimerix announced...

One of the worst performers on the Australian share market on Wednesday has been the Bionomics Ltd (ASX: BNO) share price. In morning trade the biopharmaceutical company’s shares are down a massive 37.5% to a multi-year low of 3.5 cents. Th...

At the start of every trading day, it can be useful to know which stocks are humming out of the gate. Large percentage moves in small caps aren’t uncommon, but sometimes a big announcement can cause a stock to rocket higher (or fall). Stock...

At time of writing, Bionomics share price is trading up by 62.5%, to 19.5 cents per share. Bionomics shares have traded sideways since September, when it decreased by more than 50%. Read More...